| Enhanced detection of circulating tumor DNA by fragment size analysis F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ... Science translational medicine 10 (466), eaat4921, 2018 | 876 | 2018 |
| Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer D Gale, K Heider, A Ruiz-Valdepenas, S Hackinger, M Perry, G Marsico, ... Annals of Oncology 33 (5), 500-510, 2022 | 166 | 2022 |
| ctDNA monitoring using patient-specific sequencing and integration of variant reads JCM Wan, K Heider, D Gale, S Murphy, E Fisher, F Mouliere, ... Science translational medicine 12 (548), eaaz8084, 2020 | 154 | 2020 |
| Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors CG Smith, T Moser, F Mouliere, J Field-Rayner, M Eldridge, AL Riediger, ... Genome medicine 12, 1-17, 2020 | 92 | 2020 |
| Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients F Mouliere, CG Smith, K Heider, J Su, Y van der Pol, M Thompson, ... EMBO Molecular Medicine 13 (8), e12881, 2021 | 80 | 2021 |
| Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA I Hudecova, CG Smith, R Hänsel-Hertsch, CS Chilamakuri, JA Morris, ... Genome Research 32 (2), 215-227, 2022 | 52 | 2022 |
| Detection of ctDNA from dried blood spots after DNA size selection K Heider, JCM Wan, J Hall, J Belic, S Boyle, I Hudecova, D Gale, ... Clinical Chemistry 66 (5), 697-705, 2020 | 42 | 2020 |
| Selecting short DNA fragments in plasma improves detection of circulating tumour DNA F Mouliere, AM Piskorz, D Chandrananda, E Moore, J Morris, CG Smith, ... BioRxiv, 134437, 2017 | 34 | 2017 |
| Enhanced detection of circulating tumor DNA by fragment size analysis. Sci. Transl. Med. 10, eaat4921 F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ... | 26 | 2018 |
| 379MO Datopotamab deruxtecan (Dato-DXd)+ durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC … P Schmid, PJ Wysocki, CX Ma, YH Park, R Fernandes, S Lord, RD Baird, ... Annals of Oncology 34, S337, 2023 | 23 | 2023 |
| Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018; 10 F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ... | 12 | |
| Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer A Santonja, WN Cooper, MD Eldridge, PAW Edwards, JA Morris, ... EMBO molecular medicine 15 (6), e16505, 2023 | 8 | 2023 |
| Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC. D Gale, K Heider, M Perry, G Marsico, A Ruiz-Valdepeñas, V Rundell, ... Journal of Clinical Oncology 39 (15_suppl), 8517-8517, 2021 | 8 | 2021 |
| Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models CM Sauer, K Heider, J Belic, SE Boyle, JA Hall, DL Couturier, A An, ... EMBO Molecular Medicine 14 (8), e15729, 2022 | 7 | 2022 |
| MA 11.02 circulating tumor DNA in early stage NSCLC: High sensitivity analysis in low burden disease. LUCID study update A Ruiz-Valdepenas, K Heider, G Doughton, W Qian, C Massie, ... Journal of Thoracic Oncology 12 (11), S1843-S1844, 2017 | 6 | 2017 |
| Sensitive detection of ctDNA in early-stage non-small cell lung cancer patients with a personalized sequencing assay K Heider, D Gale, A Ruiz-Valdepenas, G Marsico, G Sharma, M Perry, ... Cancer 31, 34.4, 2020 | 4 | 2020 |
| Detection of residual disease and recurrence in early-stage non-small cell lung cancer (NSCLC) patients using sensitive personalized ctDNA sequencing assays. K Heider, DG Gale, G Marsico, A Ruiz-Valdepeñas, G Sharma, M Perry, ... Journal of Clinical Oncology 38 (15_suppl), e15560-e15560, 2020 | 4 | 2020 |
| High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads JCM Wan, K Heider, D Gale, S Murphy, E Fisher, J Morris, F Mouliere, ... bioRxiv, 759399, 2019 | 4 | 2019 |
| Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated … P Schmid, PJ Wysocki, CX Ma, H Park, R Fernandes, S Lord, RD Baird, ... ANNALS OF ONCOLOGY 34, S337-S337, 2023 | 3 | 2023 |
| 57P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and … L Antonuzzo, H Takahashi, JO Park, A Sookprasert, R Gillmore, SS Yang, ... Annals of Oncology 33, S566-S567, 2022 | 3 | 2022 |
